{"id":"octreotide-drug","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Abdominal pain/discomfort"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"15-25","effect":"Gallstone formation (cholelithiasis)"},{"rate":"10-15","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Injection site pain"},{"rate":"5-10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics the natural hormone somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine tumor cells and vascular tissue. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, while also causing vasoconstriction that reduces blood supply to tumors. These dual effects make it useful in controlling hormone-related symptoms and slowing tumor growth in neuroendocrine malignancies.","oneSentence":"Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:03.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Variceal bleeding in portal hypertension"},{"name":"Neuroendocrine tumors (carcinoid syndrome, VIPoma, gastrinoma)"},{"name":"Thyroid storm"}]},"trialDetails":[{"nctId":"NCT02019706","phase":"PHASE2","title":"Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-02-12","conditions":"ACTH, Cushing's Syndrome","enrollment":80},{"nctId":"NCT00569127","phase":"PHASE3","title":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2007-12-01","conditions":"Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm","enrollment":427},{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":"Hoffa's Fat Pad Impingement","enrollment":62},{"nctId":"NCT05361668","phase":"PHASE2","title":"Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2022-04-22","conditions":"Carcinoid Syndrome, Carcinoid, Carcinoid Tumor","enrollment":36},{"nctId":"NCT07479784","phase":"PHASE3","title":"Octreotide Microspheres for Preventing Pancreatic Fistula","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-04-01","conditions":"Pancreatic Fistula","enrollment":230},{"nctId":"NCT07460908","phase":"NA","title":"Comparison of Terlipressin Versus Octreotide in Patients With Hepatorenal Syndrome","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2025-05-01","conditions":"Hepatorenal Syndrome","enrollment":60},{"nctId":"NCT07087054","phase":"PHASE3","title":"Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2025-11-19","conditions":"Carcinoid Syndrome, Carcinoid, Carcinoid Tumor","enrollment":141},{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":"Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)","enrollment":240},{"nctId":"NCT05918302","phase":"PHASE3","title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-10-27","conditions":"Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms","enrollment":120},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT07403604","phase":"PHASE1","title":"Effect of Insulin Lowering on Lipogenesis","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2026-04","conditions":"Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease","enrollment":25},{"nctId":"NCT06558422","phase":"PHASE1","title":"Human Models of Selective Insulin Resistance: Pancreatic Clamp","status":"NOT_YET_RECRUITING","sponsor":"Columbia University","startDate":"2027-01-01","conditions":"Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease","enrollment":36},{"nctId":"NCT03879694","phase":"PHASE1","title":"Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-17","conditions":"Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor","enrollment":19},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT06865677","phase":"PHASE2","title":"Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-09","conditions":"Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma","enrollment":2},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":"GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease","enrollment":288},{"nctId":"NCT05724134","phase":"PHASE1","title":"Pancreatic Clamp in NAFLD","status":"COMPLETED","sponsor":"Columbia University","startDate":"2023-08-29","conditions":"Insulin Resistance, Prediabetic State, Hyperinsulinemia","enrollment":18},{"nctId":"NCT04125836","phase":"PHASE3","title":"A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-10-10","conditions":"Acromegaly","enrollment":135},{"nctId":"NCT06441331","phase":"PHASE1","title":"Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","status":"RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2025-09-26","conditions":"Somatostatin Receptor Positive, NETs, Lymphoma","enrollment":20},{"nctId":"NCT05281328","phase":"PHASE2, PHASE3","title":"A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2022-06-28","conditions":"Polycystic Liver Disease","enrollment":71},{"nctId":"NCT06592261","phase":"PHASE1","title":"Graded Insulin Suppression Test P&F","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-09-16","conditions":"Insulin Resistance, Hyperinsulinemia, Obesity","enrollment":15},{"nctId":"NCT03624517","phase":"PHASE4","title":"Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices","status":"TERMINATED","sponsor":"Medical University of South Carolina","startDate":"2018-09-19","conditions":"Esophageal Varices, Liver Cirrhoses, Bleeding Esophageal Varices","enrollment":34},{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332},{"nctId":"NCT00262470","phase":"PHASE1, PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":"Tachycardia, Chronic Orthostatic Intolerance","enrollment":150},{"nctId":"NCT06881888","phase":"PHASE1","title":"Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-08-31","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":"Pancreatic Surgery","enrollment":655},{"nctId":"NCT04919226","phase":"PHASE3","title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":259},{"nctId":"NCT05387603","phase":"PHASE3","title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","status":"RECRUITING","sponsor":"Lund University Hospital","startDate":"2022-11-01","conditions":"Neuroendocrine Tumors","enrollment":300},{"nctId":"NCT07165886","phase":"PHASE2, PHASE3","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-29","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":243},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":"Neuroendocrine Tumors","enrollment":196},{"nctId":"NCT06193616","phase":"","title":"Outcome of ADPKD With Octreotide LAR","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2024-02-12","conditions":"Autosomal Dominant Polycystic Kidney","enrollment":70},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":"Neuroendocrine Tumors","enrollment":78},{"nctId":"NCT07104487","phase":"PHASE2","title":"[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-03-18","conditions":"Stroke (CVA) or TIA, Carotid Artery Plaque, Atherosclerosis Cardiovascular Disease","enrollment":24},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":"NETS Ga68 Lu177","enrollment":184},{"nctId":"NCT01673906","phase":"PHASE2","title":"68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours","status":"COMPLETED","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2012-08","conditions":"Neuroendocrine Tumours","enrollment":142},{"nctId":"NCT03466216","phase":"PHASE1","title":"Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET","status":"TERMINATED","sponsor":"Orano Med LLC","startDate":"2018-02-05","conditions":"Neuroendocrine Tumor","enrollment":33},{"nctId":"NCT05153772","phase":"PHASE2","title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Orano Med LLC","startDate":"2021-12-21","conditions":"Neuroendocrine Tumors","enrollment":69},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT06974344","phase":"PHASE4","title":"Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)","status":"NOT_YET_RECRUITING","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2025-06-01","conditions":"Small-for-Size Syndrome","enrollment":80},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT00113360","phase":"PHASE2","title":"RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":"Neuroendocrine Carcinoma, Islet Cell Carcinoma","enrollment":67},{"nctId":"NCT04997317","phase":"PHASE1, PHASE2","title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-21","conditions":"Meningioma","enrollment":18},{"nctId":"NCT06881628","phase":"PHASE4","title":"Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-02","conditions":"Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding, Cirrhosis","enrollment":194},{"nctId":"NCT03792555","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)","status":"COMPLETED","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2019-03-11","conditions":"Acromegaly","enrollment":13},{"nctId":"NCT02457156","phase":"PHASE3","title":"Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2015-04-23","conditions":"Pancreatic Cancer","enrollment":295},{"nctId":"NCT00463983","phase":"PHASE1, PHASE2","title":"Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2006-10","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":25},{"nctId":"NCT02795858","phase":"PHASE2","title":"A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2016-06-14","conditions":"Carcinoid Tumors","enrollment":43},{"nctId":"NCT02736448","phase":"PHASE2","title":"177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05","conditions":"Gastro-entero-pancreatic Neuroendocrine Tumors","enrollment":35},{"nctId":"NCT06753630","phase":"NA","title":"Polydeoxyribonucleotide for Elbow Lateral Epicondylitis","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2014-11-20","conditions":"Lateral Epicondylitis, Extracorporeal Shockwave Therapy, Muscle Strengthening","enrollment":48},{"nctId":"NCT04917484","phase":"PHASE2","title":"Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients","status":"RECRUITING","sponsor":"Tine Gregersen, MD","startDate":"2020-02-01","conditions":"Neuroendocrine Neoplasm","enrollment":100},{"nctId":"NCT05833217","phase":"NA","title":"Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-06-06","conditions":"Long COVID, Insulin Resistance, Insulin Sensitivity","enrollment":55},{"nctId":"NCT04871204","phase":"PHASE2","title":"Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer","status":"COMPLETED","sponsor":"Fredrik Klevebro","startDate":"2021-06-16","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":20},{"nctId":"NCT06505395","phase":"PHASE2","title":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07-30","conditions":"Gastrointestinal Neuroendocrine Pancreatic Tumor","enrollment":90},{"nctId":"NCT06045260","phase":"PHASE2","title":"\"Receptor Radionuclide Therapy With 177Lu-DOTATOC","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2023-09-13","conditions":"Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma","enrollment":100},{"nctId":"NCT01424241","phase":"PHASE4","title":"Effects of Sandostatin LAR® in Acromegaly","status":"COMPLETED","sponsor":"Columbia University","startDate":"2006-10","conditions":"Acromegaly","enrollment":21},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT05701241","phase":"PHASE4","title":"Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2023-06-28","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":270},{"nctId":"NCT04076462","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-08-19","conditions":"Acromegaly","enrollment":72},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":"Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","enrollment":16},{"nctId":"NCT01070758","phase":"PHASE4","title":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-02","conditions":"Congenital Hyperinsulinism","enrollment":3},{"nctId":"NCT05749289","phase":"PHASE2, PHASE3","title":"Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-12-20","conditions":"Neuroendocrine Tumor","enrollment":400},{"nctId":"NCT06300216","phase":"","title":"A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-03-26","conditions":"Neuroendocrine Tumors","enrollment":500},{"nctId":"NCT04048707","phase":"PHASE2","title":"Angiotensin 2 for Hepatorenal Syndrome","status":"WITHDRAWN","sponsor":"University of California, Los Angeles","startDate":"2021-07-01","conditions":"Hepatorenal Syndrome, Cirrhosis, Kidney Failure, Acute","enrollment":""},{"nctId":"NCT03179995","phase":"PHASE2","title":"Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2017-07-07","conditions":"Major Liver Resection","enrollment":23},{"nctId":"NCT06254235","phase":"PHASE1","title":"Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-06-16","conditions":"Healthy Volunteers","enrollment":240},{"nctId":"NCT03724409","phase":"EARLY_PHASE1","title":"Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases","status":"TERMINATED","sponsor":"Sandeep Laroia","startDate":"2018-10-11","conditions":"Neuroendocrine Tumors","enrollment":3},{"nctId":"NCT02385617","phase":"NA","title":"Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2014-01","conditions":"Esophageal Neoplasms, Stomach Neoplasms, Weight Loss","enrollment":20},{"nctId":"NCT02381249","phase":"NA","title":"The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2015-03","conditions":"Esophageal Neoplasms, Stomach Neoplasms, Weight Loss","enrollment":40},{"nctId":"NCT06080204","phase":"NA","title":"Real-world Study on Adjuvant Octreotide Therapy in pNETs","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2008-03","conditions":"Pancreatic Neuroendocrine Tumor G2","enrollment":411},{"nctId":"NCT06085976","phase":"PHASE2","title":"Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2023-08-14","conditions":"Hepatic Carcinoma, Hepatic Metastasis","enrollment":62},{"nctId":"NCT05761431","phase":"PHASE1","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-03-02","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT06062719","phase":"PHASE2, PHASE3","title":"Role of Octreotide in Non Variceal Bleeding","status":"UNKNOWN","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2023-08-23","conditions":"Non-variceal Gastrointestinal Bleeding","enrollment":56},{"nctId":"NCT03044977","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Bushnell","startDate":"2017-05-07","conditions":"Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting","enrollment":20},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":220},{"nctId":"NCT00427349","phase":"PHASE2","title":"AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-11-07","conditions":"Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome","enrollment":46},{"nctId":"NCT00003057","phase":"PHASE3","title":"Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1997-03-26","conditions":"Colorectal Cancer, Diarrhea","enrollment":500},{"nctId":"NCT00003283","phase":"PHASE2","title":"Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1998-10-13","conditions":"Thymoma and Thymic Carcinoma","enrollment":38},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT02333565","phase":"PHASE2","title":"Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2015-01-22","conditions":"Recurrent Meningiomas, Resistant Meningiomas","enrollment":20},{"nctId":"NCT02384122","phase":"PHASE3","title":"Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":"Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage","enrollment":62},{"nctId":"NCT04941911","phase":"PHASE2","title":"A Feasibility Study of Octreotide Infusion During Liver Transplant.","status":"UNKNOWN","sponsor":"University College, London","startDate":"2022-05-27","conditions":"Liver Transplantation, Renal Failure","enrollment":30},{"nctId":"NCT05683444","phase":"EARLY_PHASE1","title":"Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2020-07-01","conditions":"Lymphatic Diseases, Chylothorax","enrollment":16},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":"Acromegaly","enrollment":39},{"nctId":"NCT04276597","phase":"PHASE2","title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","status":"WITHDRAWN","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2020-03-04","conditions":"Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT02335580","phase":"","title":"Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2014-12","conditions":"Liver Cirrhosis, Portal Vein, Venous Thrombosis","enrollment":475},{"nctId":"NCT04915144","phase":"PHASE2","title":"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs","status":"WITHDRAWN","sponsor":"British Columbia Cancer Agency","startDate":"2023-01-15","conditions":"Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor","enrollment":""},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":"Neuroendocrine Tumors, Meningioma, Neuroblastoma","enrollment":39},{"nctId":"NCT03891849","phase":"NA","title":"Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-09-01","conditions":"Haemorrhagic Shock, Variceal Hemorrhage","enrollment":""},{"nctId":"NCT05682209","phase":"PHASE4","title":"The Effect of Octreotide on Wound Drainage After Mastectomy","status":"COMPLETED","sponsor":"Ikechukwu Bartholomew Ulasi","startDate":"2020-12-18","conditions":"Seroma Following Procedure","enrollment":41},{"nctId":"NCT01538966","phase":"NA","title":"Acromegaly Combination Treatment Study","status":"TERMINATED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-03-29","conditions":"Acromegaly","enrollment":76},{"nctId":"NCT01613495","phase":"NA","title":"Ghrelin Suppression by Octreotide in Prader-Willi","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-08","conditions":"Prader Willis Syndrome","enrollment":2},{"nctId":"NCT04027348","phase":"PHASE2","title":"Palliative Management of Inoperable Malignant Bowel Obstruction","status":"TERMINATED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-26","conditions":"Malignant Bowel Obstruction","enrollment":15},{"nctId":"NCT01086982","phase":"PHASE1","title":"Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ®","status":"SUSPENDED","sponsor":"Azidus Brasil","startDate":"2010-03","conditions":"Acromegaly","enrollment":16},{"nctId":"NCT03541447","phase":"PHASE2","title":"Tolvaptan-Octreotide LAR Combination in ADPKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-12-12","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":20},{"nctId":"NCT01229943","phase":"PHASE2","title":"Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-15","conditions":"Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Pancreatic Gastrinoma","enrollment":150},{"nctId":"NCT02010385","phase":"NA","title":"Investigation of the Effects of Obesity Surgery on Appetitive Behaviour","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2013-02","conditions":"Roux-en-Y Bariatric Surgery","enrollment":30},{"nctId":"NCT05199038","phase":"PHASE4","title":"Comparison of 2 Days Versus 5 Days of Octreotide After Endoscopic Therapy in Preventing Early Esophageal Varices Rebleed : A Randomized Controlled Study","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2022-06","conditions":"Esophageal Varices","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Octreotide acetate","Octreotide and 1-O-n-Dodecyl-b-D-Maltoyranoside (DDM) (Intravail®)","Sandostatin®","Somatostatin analogue"],"phase":"marketed","status":"active","brandName":"Octreotide (drug)","genericName":"Octreotide (drug)","companyName":"Lahore General Hospital","companyId":"lahore-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octreotide is a somatostatin analog that binds to somatostatin receptors on neuroendocrine cells and blood vessels to inhibit the secretion of various hormones and reduce blood flow to tumors. Used for Acromegaly, Variceal bleeding in portal hypertension, Carcinoid syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}